Special Issue "Targeting Head and Neck Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2019).
Interests: head and neck cancer; molecular biology; imaging; rehabilitation
Interests: head and neck cancer, molecular biology, translational medicine
Interests: head and neck cancer, translational research, novel treatments
Targeted therapies in head and neck cancer are crucial to personalizing treatment and improving outcomes. Genetic profiling of tumors has shown several subtypes, but currently only HPV-associated tumors are seen as a distinct entity. Also, subtypes with more DNA repair deficits, hypoxia, EMT, and other pathway aberrations have been identified. Unfortunately, this has not yet led to different treatment protocols. Chemotherapy and small molecules have so far not played an important role in the curative setting in head and neck cancer. However, in the palliative setting, especially in salivary gland cancer, more targeted therapies are becoming available, and in several basket trials genetic profiling is used to select the most optimal strategy. In the neoadjuvant setting, chemotherapy, targeted molecules, and immunotherapy are being explored. As radiosensitizers, so far only cisplatin and cetuximab are widely used, but no reliable biomarkers are used to predict a response. PARP inhibition has been shown to act as a strong radiosensitizer and is currently under investigation. A major issue is the lack of reliable biomarkers and in vitro systems to predict a response. In this issue, several aspects of targeted treatment will be covered. Researchers studying biomarkers, as well as model systems and trials using a targeted approach, are invited to submit manuscripts.
Prof. Dr. Michiel Wilhelmus Maria van den Brekel
Dr. Bhuvanesh Singh
Dr. Charlotte Zuur
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- targeted therapy
- head and neck cancer
- model systems
- pathway inhibition
- salivary gland carcinoma
- personalized medicine